Chronic Posttransfusion Non-A, Non-B Hepatitis and Autoimmune Chronic Active Hepatitis - Aspects on Treatment, Prognosis and Relation to Hepatitis C Virus

References

• Krugman S, Giles J, Hammond J. Infectious hepatitis: Evidence for two distinctive clinical, epidemiological and immunological types of infection. JAMA 200:365–73,1967
   PubMed Web of Science ®Google Scholar
• Blumberg B, Alter H, Visnich S. A “new” antigen in leukemia sera. JAMA 191:541–46,1965
   PubMed Web of Science ®Google Scholar
• Blumberg B, Gerstley B, Hungerford D, London W, Sutnick A. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 66:924–31,1967
   PubMed Web of Science ®Google Scholar
• Feinstone S, Kapikian A, Purcell R. Hepatitis A: Detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 182:1026–28,1973
   PubMed Web of Science ®Google Scholar
• Rizetto M, Canese M, Aricó S, Crivelli O, Trepo C, Bonino F, Verme G. Immunofluorescence detection of new antigen-antibody system (∂/anti-∂) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 18:997–1003,1977
   PubMed Web of Science ®Google Scholar
• Reyes G, Purdy M, Kim J, Luk K, Young L, Fry K, Bradley D. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 247:1335–39,1990
   PubMed Web of Science ®Google Scholar
• Choo Q, Kuo G, Weiner A, Overby L, Bradley D, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359–62,1989
   PubMed Web of Science ®Google Scholar
• Bradley D. Hepatitis non-A, non-B viruses become identified as hepatitis C and E viruses. In Melnick JL (ed): Prog Med Virol, Basel, Karger 37:pp 101–135,1990
   Google Scholar
• Iwarson S, Lundin P, Holmgren J, Hermodsson S. Multiple attacks of hepatitis in drug addicts: Biochemical, immunochemical, and morphologic characteristics. J Infect Dis 127:544–50,1973
   PubMed Web of Science ®Google Scholar
• Alter H, Purcell R, Holland P, Feinstone S, Morrow A, Moritsugu Y. Clinical and serological analysis of transfusion-associated hepatitis. Lancet ii:838–41,1975
   Web of Science ®Google Scholar
• Feinstone S, Kapikian A, Purcell R, Alter H, Holland P. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 292:767–70,1975
   PubMed Web of Science ®Google Scholar
• Prince A, Brotman B, Grady G, Kuhns W, Hazzi C, Levine R, Millian S. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet ii:241–46,1974
   Google Scholar
• Dienstag J.. Non-A, non-B hepatitis I. Recognition, epidemiology, and clinical features. Gastroenterology 85:439–462,1983
   PubMed Web of Science ®Google Scholar
• Kuo G, Choo Q, Alter H, Gitnick G, Redeker A, Purcell R, Miyamura T, Dienstag J, Alter M, Stevens C, Tegtmeier G, Bonino F, Colombo M, Lee W, Kuo C, Berger K, Shuster J, Overby L, Bradley D, Houghton M. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362–64,1989
   PubMed Web of Science ®Google Scholar
• Martin P. Hepatitis C: From laboratory to bedside (editorial). Mayo Clin Proc 65:1372–76,1990
   Google Scholar
• Weiland O, Lindh G, Mattsson L, Schvarcz R, von Sydow M. Hepatit C en vanlig orsak till kronisk hepatit i Sverige. Läkartidningen 34:2567–68,1990 (in Swedish).
   Google Scholar
• Alter M, Hadler S, Judson F, Mares A, Alexander J, Hu P, Miller J, Moyer L, Fields H, Bradley D, Margolis H. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 264:2231–35,1990
   PubMed Web of Science ®Google Scholar
• Alter H, Purcell R, Shih J, Melpolder J, Houghton M, Choo Q, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321:1494–1500,1989
   PubMed Web of Science ®Google Scholar
• Esteban J, Gonzalez A, Hernandez J, Viladomiu L, Sanchez C, Lopez-Talavera J, Lucea D, Martin-Vega C, Vidal X, Esteban R, Guardia J. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med 323:1107–12,1990
   PubMed Web of Science ®Google Scholar
• Van der Poel C, Reesink H, Schaasberg W, Leentvaar-Luypers A, Bakker E, Exel-Oehlers P, Lelie P. Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet 335:558–60,1990
   PubMed Web of Science ®Google Scholar
• Ebeling F, Naukkarinen R, Leikola J. Recombinant immunoblot assay for hepatitis C virus antibody as predictor of infectivity. Lancet 335:982–83,1990
   PubMed Web of Science ®Google Scholar
• Van Der Poel C, Cuypers H, Reesink H, Weiner A, Quan S, Di Nello R, Van Boven J, Winkel I, Mulder-Folkerts D, Exel-Ohlers P, Schaasberg W, Leentvaar-Kuypers A, Polito A, Houghton M, Lelie P. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 337:317–19,1991
   PubMed Web of Science ®Google Scholar
• Weiner A, Truett M, Rosenblatt J, Han J, Quan S, Polito A, Kuo G, Choo Q, Houghton M, Agius C, Page E, Nelles M. HCV testing in low-risk population. Lancet 336:695,1990
   PubMed Web of Science ®Google Scholar
• Mimms L, Vallari D, Ducharme L, Holland P, Kuramoto I, Zeldis J. Specificity of anti-HCV ELISA assessed by reactivity to three immunodominant HCV regions. Lancet 336:1590–91,1990
   PubMed Web of Science ®Google Scholar
• Muraiso K, Hijikata M, Ohkoshi S, Cho M, Kikuchi M, Kato N, Shimotohno K. A structural protein of hepatitis C virus expressed in E. coli facilitates accurate detection of hepatitis C virus. Biochem Biophys Res Commun 172:511–16,1990
   Google Scholar
• Mishiro S, Hoshi Y, Takeda K, Yoshikawa A, Gotanda T, Takahashi K, Akahane Y, Yoshizawa H, Okamoto H, Tsuda F, Peterson D, Muchmore E. Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: Implication for an autoimmune process. Lancet 336:1400–03,1990
   PubMed Web of Science ®Google Scholar
• Yoshizawa H, Nojiri N, Takahashi K. Measurement of anti-GOR antibodies in prevention of post-transfusion non-A, non-B hepatitis. Lancet 337:47–48,1991
   Google Scholar
• Weiner A, Kuo G, Bradley D, Bonino F, Saracco G, Lee C, Rosenblatt J, Choo Q, Houghton M. Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet 335:1–3,1990
   PubMed Web of Science ®Google Scholar
• Garson J, Tedder R, Briggs M, Tuke P, Glazebrook J, Trute A, Parker D, Barbara J, Contreras M, Aloysius S. Detection of hepatitis C viral sequences in blood donations by “nested” polymerase chain reaction and prediction of infectivity. Lancet 335:1419–22,1990
   PubMed Web of Science ®Google Scholar
• Zanetti A, Tanzi E, Zehender G, Magni E, Incarbone C, Zonaro A, Primi D, Cariani E. Hepatitis C virus RNA in symptomless donors implicated in post-transfusion non-A, non-B hepatitis. Lancet 336:448,1990
   Google Scholar
• Garson J, Tuke P, Makris M, Briggs M, Machin S, Preston F, Tedder R. Demonstration of viremia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates. Lancet 336:1022–25,1990
   PubMed Web of Science ®Google Scholar
• Mattsson L, Åberg B, Weiland O, Sellman M, Davilén J. Non-A, non-B hepatitis after open-heart surgery in Stockholm: Declining incidence after introduction of restrictions for blood donations due to the human immunodeficiency virus. Scand J Infect Dis 20:371–76,1988
   PubMed Web of Science ®Google Scholar
• Koretz R, Stone O, Mousa M, Gitnick G. Non-A, non-B posttransfusion hepatitis - a decade later. Gastroenterology 88:1251–54,1985
   PubMed Web of Science ®Google Scholar
• Feinman S, Berris B, Bojarski S. Posttransfusion hepatitis in Toronto, Canada. Gastoenterology 95:464–69,1988
   PubMed Web of Science ®Google Scholar
• Dienstag J, Alter H. Non-A, non-B hepatitis: Evolving epidemiologic and clinical perspective. Semin Liv Dis 6:67–81,1986
   PubMed Web of Science ®Google Scholar
• Realdi G, Alberti A, Rugge M, Rigoli A, Tremolada F, Schivazappa L, Ruol A. Long-term follow-up of acute and chronic non-A, non-B posttransfusion hepatitis: Evidence of progression to liver cirrhosis. Gut 23:270–75,1982
   PubMed Web of Science ®Google Scholar
• Mattsson L, Weiland O, Glaumann H. Chronic non-A, non-B hepatitis developed after transfusions, illicit self-injections or sporadically. Outcome during long-term follow-up - a comparison. Liver 9:120–127,1989
   PubMedGoogle Scholar
• Mattsson L, Weiland O, Glaumann H. Application of a numerical scoring system for assessment of histological outcome in patients with chronic posttransfusion non-A, non-B hepatitis with or without antibodies to hepatitis C. Liver 10:257–63,1990
   PubMedGoogle Scholar
• Hoofnagle J, Di Bisceglie A, Lisker-Melman M, Kassianides C, Martin P. Management of post-transfusion hepatitis. Transfus Med Rev 2:215–20,1988
   Google Scholar
• Mattsson L. Chronic non-A, non-B hepatitis with special reference to the transfusion-associated form. Scand J Infect Dis (suppl 59) 21:1–55,1989
   PubMedGoogle Scholar
• Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshisawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell R, Alter H. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 12:671–75,1990
   PubMed Web of Science ®Google Scholar
• Koretz R, Coleman E, Abbey H, Gitnick G. Non-A, non-B post-transfusion hepatitis: When is a disease a dis-ease? (abstract) Hepatology 10:645,1989
   Google Scholar
• Hay C, Preston F, Triger D, Underwood J. Progressive liver disease in haemophilia: An underestimated problem? Lancet i:1495–98,1985
   Google Scholar
• Björkander J, Cunningham-Rundles C, Lundin P, Olsson R, Söderström R, Hanson L. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med 84:107–11,1988
   PubMed Web of Science ®Google Scholar
• Weiland O, Mattsson L, Glaumann H. Non-A, non-B hepatitis after intravenous gammaglobulin. Lancet i:976–77,1986
   Google Scholar
• Martin P, Di Bisceglie A, Kassianides C, Lisker-Melman M, Hoofnagle J. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 97:1559–61,1989
   PubMed Web of Science ®Google Scholar
• Bruix J, Barrera J, Calvet X, Ercilla G, Costa J, Sanchez-Tapias J, Ventura M, Vall M, Bruguera M, Bru C, Castillo R, Rodes J. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet ii:1004–06,1989
   Google Scholar
• Colombo M, Kuo G, Choo Q, Donato M, Del Ninno E, Tommasini M, Dioguardi N, Houghton M. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet ii:1006–08,1989
   Google Scholar
• Hasan F, Jeffers L, De Medina M, Reddy K, Parker T, Schiff E, Houghton M, Choo Q, Kuo G. Hepatitis C-associated hepatocellular carcinoma. Hepatology 12:589–91,1990
   PubMed Web of Science ®Google Scholar
• Sbolli G, Zanetti A, Tanzi E, Cavanna L, Civardi G, Fornari F, Di Stasi M, Buscarini L. Serum antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. J Med Virol 30:230–32,1990
   PubMedGoogle Scholar
• Colombo M, Oldani S, Donato M, Borzio M, Santese R, Roffi L, Vigano P, Cargnel A. A multicenter, prospective study of posttransfusion hepatitis in Milan. Hepatology 7:709–12,1987
   PubMed Web of Science ®Google Scholar
• Mattsson L, Åberg B, von Sydow M, Weiland O. Incidence of hepatitis and seroconversion to hepatitis C virus after open-heart surgery in transfused and non-transfused patients in Sweden. Scand J Infect Dis 23:25–29,1991
   PubMed Web of Science ®Google Scholar
• Van der Poel C, Reesink H, Lelie P, Leentvaar-Luypers A, Choo Q, Kuo G, Houghton M. Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in the Netherlands. Lancet ii:297–98,1989
   Google Scholar
• Kühnl P, Seidl S, Stangel W, Beyer J, Sibrowski W, Flik J. Antibody to hepatitis C virus in German blood donors. Lancet ii:324,1989
   Google Scholar
• Lindholm A, Hermodsson S, Norkrans G, Iwarson S. Nytt serologiskt test ger möjlighet att diagnosticera hepatit C. Läkartidningen 87:40–1,1990 (in Swedish).
   PubMedGoogle Scholar
• Menitove J, Richards W, Destree M. Early US experience with anti-HCV kit in blood donors. Lancet 336:244–45,1990
   PubMedGoogle Scholar
• Stevens C, Taylor P, Pindyck J, Choo Q, Bradley D, Kuo G, Houghton M. Epidemiology of hepatitis C virus: A preliminary study in volunteer blood donors. JAMA 263:49–53,1990
   PubMed Web of Science ®Google Scholar
• Alter M, Coleman P, Alexander J, Kramer E, Miller J, Mandel E, Hadler S, Margolis H. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 262:1201–05,1989
   PubMed Web of Science ®Google Scholar
• Esteban J, Esteban R, Viladomiu L, López-Talavera J, Gonzáles A, Hernández A, Roget M, Vargas V, Genescá J, Buti M, Guardia J, Houghton M, Choo Q, Kuo G. Hepatitis C virus antibodies among risk groups in Spain. Lancet ii:294–297,1989
   Google Scholar
• Tor J, Llibre J, Carbonell M, Muga R, Ribera A, Soriano V, Clotet B, Sabriá M, Foz M. Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV. Br Med J 301:1130–33,1990
   PubMed Web of Science ®Google Scholar
• Sönnerborg A, Abebe A, Strannegård Ö. Hepatitis C virus infection in individuals with or without human immunodeficiency virus type 1 infection. Infection 18:347–51,1990
   PubMedGoogle Scholar
• Widell A, Hansson B, Berntorp E, Moestrup T, Johansson H, Hansson H, Nordenfeldt E. Antibody to a hepatitis C virus related protein among patients at high risk for hepatitis B. Scand J Infect Dis 23:19–24,1991
   PubMed Web of Science ®Google Scholar
• Wejstål R, Hermodsson S, Iwarson S, Norkrans G. Mother to infant transmission of hepatitis C virus infection. J Med Virol 30:178–80,1990
   PubMed Web of Science ®Google Scholar
• Schulman S, Grillner L. Antibodies against hepatitis C in a population of Swedish haemophiliacs and heterosexual partners. Scand J Infect Dis 22:393–97,1990
   PubMed Web of Science ®Google Scholar
• Kiese M, Lenz K, Guggenmoos-Holzmann I, Stark K, Bienzle U. Epidemiology of hepatitis C in homosexual men. Klin Wochenschr 68:1082,1990
   PubMedGoogle Scholar
• Takamatsu K, Koyanagi Y, Okita K, Yamamoto N. Hepatitis C virus RNA in saliva. Lancet 336:1515,1990
   PubMedGoogle Scholar
• Dusheiko G, Smith M, Scheuer P. Hepatitis C virus transmitted by human bite. Lancet 336:503–04,1990
   PubMed Web of Science ®Google Scholar
• Grossberg S. Interferons: An overview of their biological and biochemical properties. In: Mechanism of interferon actions. L.M. Pfeffer (ed), CRC Press, Inc, Boca Raton, Florida vol I:pp 1–32,1987
   Google Scholar
• Perillo R, Schiff E, Davis G, Bodenheimer H, Lindsay K, Payne J, Dienstag J, O'Brien C, Tamburro C, Jacobson I, Sampliner R, Feit D, Lefkowitch J, Kuhns M, Meschiewitz C, Sanghvi B, Albrecht J, Gibas A, and the Hepatitis Interventional Therapy Group. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 323:295–301,1990
   PubMed Web of Science ®Google Scholar
• Alexander G, Brahm J, Fagan E, Smith H, Daniels H, Eddleston A, Williams R. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet ii: 66–69,1987
   Google Scholar
• Hoofnagle J. Alpha-interferon therapy of chronic hepatitis B. Current status and recommendations. J Hepatol (suppl) 11:100–107,1990
   Google Scholar
• Thomas H. The hepatitis B virus and the host response. J Hepatol (suppl) 11:83–89,1990
   Google Scholar
• Di Bisceglie A, Martin P, Lisker-Melman M, Kassianides C, Korenman J, Bergasa N, Baker B, Hoofnagle J. Therapy of chronic delta hepatitis with interferon alfa-2b. J Hepatol (suppl) 11:151–54,1990
   Google Scholar
• Hoofnagle J, Mullen K, Jones D, Rustgi V, Di Bisceglie A, Peters M, Waggoner J, Park Y, Jones E. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315:1575–1578,1986
   PubMed Web of Science ®Google Scholar
• Schvarcz R, Weiland O, Glaumann H. Alpha interferon treatment of chronic non-A, non-B hepatitis caused by intravenous gammaglobulin. Scand J Infect Dis 20:231–232,1988
   PubMed Web of Science ®Google Scholar
• Thomson B, Doran M, Lever A, Webster A. Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet i:539–541,1987
   Google Scholar
• Saracco G, Rosina M, Torrani Cerenzia M, Lattore V, Chiandussi L, Gallo V, Petrino R, De Micheli A, Donegani E, Solinas A, Deplano A, Tocco A, Cossu P, Pintus C, David E, Mazzucco G, Verme G, Rizzetto M. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol (suppl) 11:43–49,1990
   PubMedGoogle Scholar
• Realdi G, Diodati G, Bonetti P, Scaccabarozzi S, Alberti A, Ruol A. Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized controlled trial. J Hepatol (suppl) 11:68–71,1990
   PubMed Web of Science ®Google Scholar
• Marcellin P, Boyer N, Giostra E, Degott C, Degos F, Copperé H, Calès P, Couzigou P, Martinot M, Loriot M, Benhamou J. Better efficacy of high dose versus low dose recombinant interferon alpha 2 b treatment in chronic non A non B hepatitis (abstract). Hepatology 10:646,1989
   Google Scholar
• Gómez-Rubio M, Porres J, Castillo I, Quiroga J, Moreno A, Carreno V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol (suppl) 11:63–67,1990
   PubMedGoogle Scholar
• Davis G, Balart L, Schiff E, Linsday K, Bodenheimer H, Perillo R, Carey W, Jacobsson I, Payne J, Dienstag J, VanThiel D, Tamburro C, Lefkowitsch J, Albrecht J, Meschievitz C, Ortego T, Gibas A, and the Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 321:1501–1506,1989
   PubMed Web of Science ®Google Scholar
• Di Bisceglie A, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks S, Hoofnagle J. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506–1510,1989
   PubMed Web of Science ®Google Scholar
• Davis G. Recombinant alpha-interferon treatment of non-A, non-B (type C) hepatitis: Review of studies and recommendations for treatment. J Hepatol (suppl) 11:72–77,1990
   Google Scholar
• Ferenci P, Vogel W, Pristautz H, Deimer J, Denk H, Judmaier G, Maier K, Krejs G, Gangl A. One-year treatment of chronic non-A, non-B hepatitis with interferon alfa-2b. J Hepatol (suppl) 11:50–53,1990
   Google Scholar
• Causse X, Godinot H, Ouzan D, Chossegros P, Chevallier M, Meschievitz C, Trépo C. Recombinant alpha interferon for chronic non-A, non-B hepatitis: Optimal dose and factors associated with favorable response (abstract). Hepatology 10:643,1989
   Google Scholar
• Wejstål R, Norkrans G, Weiland O, Schvarcz R, Fuchs D, Wachter H, Frydén A, Glaumann H. Lymphocyte subset and β2-microglobulin expression in chronic non-A, non-B hepatitis - effects of alpha-interferon treatment. Submitted.
   Google Scholar
• Kanai K, Iwata K, Nakao K, Kako M, Okamoto H. Suppression of hepatitis C virus RNA by interferon alpha. Lancet 336:245,1990
   PubMed Web of Science ®Google Scholar
• Schulz M, Brabant G, von zur Mühlen A, Müller R. Induction of autoimmune thyroid disease by treatment with recombinant interferon alpha in patients with chronic NANB-hepatitis (abstract). J Hepatol (suppl) 9:223,1989
   Google Scholar
• Stokes P, Lopez W, Balart L. Effects of short-term corticosteroid therapy in patients with chronic non-A, non-B hepatitis (abstract). Gastroenterology 92:1783,1987
   Web of Science ®Google Scholar
• Hoofnagle J. Chronic hepatitis: The role of corticosteroids. In: Viral Hepatitis, Szmuness W, Alter HJ, Maynard JE (eds). 1981 International Symposium, Philadelphia, Franklin Press, pp 573–83,1982
   Google Scholar
• Pappas S, Hoofnagle J, Young N, Straus S, Jones E. Treatment of chronic non-A, non-B hepatitis with acyclovir: Pilot study. J Med Virol 15:1–9,1985
   PubMed Web of Science ®Google Scholar
• Reichard O, Andersson J. Ribavarin: A possible alternative for the treatment of chronic non-A, non-B hepatitis. Scand J Infect Dis 22:509, 1990
   PubMed Web of Science ®Google Scholar
• Waldenström J. Leber, Blutproteine und Nahrungseiweiss. In: Dtsch. Z Verdgs. -u. Stoffwechs. -Krh., Sonderband: XV. Tagung, Bad Kissingen, pp 113–21,1950
   Google Scholar
• Keating J, O'Brien C, Stellon A, Portmann B, Johnson R, Johnson P, Williams R. Influence of aetiology, clinical and histological features on survival in chronic active hepatitis: An analysis of 204 patients. Q J Med 237:59–66,1987
   Google Scholar
• Mistilis S, Blackburn C. Active chronic hepatitis. Am J Med 48:484–95,1970
   PubMed Web of Science ®Google Scholar
• Eddleston A. Immunology of chronic active hepatitis. Q J Med 218:191–98,1985
   Google Scholar
• Czaja A. Current problems in the diagnosis and management of chronic active hepatitis. Mayo Clin Proc 56:321–323,1981
   Google Scholar
• Vento S, Nouri-Aria K, Eddleston A. Immune mechanisms in autoimmune chronic active hepatitis. Scand J Gastroenterol (suppl) 20:91–103,1985
   Google Scholar
• Robertson D, Zhang S, Guy E, Wright R. Persistent measles virus genome in autoimmune chronic active hepatitis. Lancet ii:9–11,1987
   Google Scholar
• Homberg J, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil S, Poupon R, Darnis F, Lévy V, Grippon P, Opolon P, Bernuau J, Benhamou J, Alagille D. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: A second type of “autoimmune” hepatitis. Hepatology 7:1333–39,1987
   PubMed Web of Science ®Google Scholar
• Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde K. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet i:292–94, 1987
   Google Scholar
• Murray-Lion I, Stern R, Williams R. Controlled trial of prednisone and azathoprine in active chronic hepatitis. Lancet i:735–37, 1973
   Google Scholar
• Cook G, Mulligan R, Sherlock S. Controlled trial of corticosteroid therapy in chronic active hepatitis. Q J Med 40:159–185, 1971
   PubMedGoogle Scholar
• Soloway R, Summerskill W, Baggenstoss A, Geall M, Gitnick G, Elveback L, Schoenfield L. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 63:820–833, 1972
   PubMed Web of Science ®Google Scholar
• Hegarty J, Nouri Aria K, Portmann B, Eddleston A, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 3:685–89, 1983
   PubMed Web of Science ®Google Scholar
• Czaja A, Beaver S, Shiels M. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 92:215–9, 1987
   PubMed Web of Science ®Google Scholar
• Czaja A, Ludwig J, Baggenstoss A, Wolf A. Corticosteroid-treated chronic active hepatitis in remission: Uncertain prognosis of chronic persistent hepatitis. N Engl J Med 304:5–9, 1981
   PubMed Web of Science ®Google Scholar
• Czaja A, Davis G, Ludwig J, Taswell H. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 4:622–27, 1984
   PubMed Web of Science ®Google Scholar
• McFarlane I, Hegarty J, McSorley C, McFarlane B, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet ii:954–56, 1984
   Google Scholar
• Sherlock S. Chronic hepatitis and cirrhosis. Hepatology (suppl) 4:25–28, 1984
   PubMed Web of Science ®Google Scholar
• Davis G, Czaja A, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 87:1222–7, 1984
   PubMed Web of Science ®Google Scholar
• Czaja A, Ammon H, Summerskill W. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 78:518–523, 1980
   PubMed Web of Science ®Google Scholar
• Czaja A, Davis G, Ludwig J, Baggenstoss A, Taswell H. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 85:713–717, 1983
   PubMedGoogle Scholar
• Kirk A, Jain S, Pocock S, Thomas H, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 21:78–83, 1980
   PubMed Web of Science ®Google Scholar
• Dussaix E, Maggiore G, De Giacomo C, Mondelli M, Martres P, Alvarez F. Autoimmune hepatitis in children and hepatitis C virus testing. Lancet 335:1160–61, 1990
   Google Scholar
• Di Bisceglie A, Alter H, Kuo G, Houghton M, Hoofnagle J. Detection of antibody to hepatitis C virus in patients with various chronic liver diseases (abstract). Hepatology 10:581,1989
   Google Scholar
• Schrumpf E, Elgjo K, Fausa O, Haukenes G, Kvale D, Rollag H. The significance of anti-hepatitis C virus antibodies measured in chronic liver disease. Scand J Gastroenterol 25:1169–74,1990
   PubMed Web of Science ®Google Scholar
• Lenzi M, Ballardini G, Fusconi M, Cassani F, Selleri L, Volta U, Zauli D, Bianchi F. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet 335:258–59,1990
   PubMed Web of Science ®Google Scholar
• McFarlane I, Smith H, Johnson P, Bray G, Vergani D, Williams R. Hepatitis C virus antibodies in chronic active hepatitis: Pathogenetic factor or false-positive result? Lancet 335:754–57,1990
   PubMed Web of Science ®Google Scholar
• Aceti A, Taliani G, De Bac C, Sebastiani A. Anti-HCV false positivity in malaria. Lancet 336:1442–43,1990
   PubMed Web of Science ®Google Scholar
• Boudart D, Lucas J, Muller J, Le Carrer D, Planchon B, Harousseau J. False-positive hepatitis C virus antibody tests in paraproteinaemia. Lancet 336:63,1990
   PubMedGoogle Scholar
• Fusconi M, Lenzi M, Ballardini G, Miniero R, Cassani F, Zauli D, Bianchi F. Anti-HCV testing in autoimmune hepatitis and primary biliary cirrhosis. Lancet 336:823,1990
   PubMedGoogle Scholar
• Theilmann L, Blazek M, Goeser T, Gmelin K, Kommerell B, Fiehn W. False-positive anti-HCV tests in rheumatoid arthritis. Lancet 335:1346,1990
   PubMedGoogle Scholar
• Gray J, Wreghitt T, Friend P, Wight D, Sundaresan V, Calne R. Differentiation between specific and non-specific hepatitis C antibodies in chronic liver disease. Lancet 335:609–10,1990
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Toda G, Hashimoto N, Kurokawa K. Antibody to superoxide dismutase, autoimmune hepatitis, and antibody tests for hepatitis C virus. Lancet 335:1345–46,1990
   PubMedGoogle Scholar
• Wong D, Diwan A, Rosen L, Gerin J, Johnson R, Polito A, Purcell R. Non-specificity of anti-HCV test for seroepidemiological analysis. Lancet 336:750–51,1990
   PubMedGoogle Scholar
• Mortimer P, Cohen B, Litton P, Vandervelde E, Bassendine M, Brind A, Hambling M. Hepatitis C virus antibody. Lancet ii:798,1989
   Google Scholar
• Ellis L, Brown D, Conradie J, Paterson A, Sher R, Millo J, Theodossiadou E, Dusheiko G. Prevalence of hepatitis C in South Africa: Detection of anti-HCV in recent and stored serum. J Med Virol 32:249–51,1990
   PubMed Web of Science ®Google Scholar
• Knodell R, Ishak K, Black W, Chen T, Craig R, Kaplowitz T, Kieman T, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435,1981
   PubMed Web of Science ®Google Scholar
• Dienes H, Popper H, Arnold W, Lobeck H. Histologic observations in human hepatitis non-A, non-B. Hepatology 2:562–71,1982
   PubMed Web of Science ®Google Scholar
• Peto R, Pike M, Armitage P, Breslow N, Cox D, Howard S, Mantel N, McPehrson K, Peto J, Smith P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 35:1–39, 1977
   PubMed Web of Science ®Google Scholar
• Mattsson L, Weiland O, Glaumann H. Long-term follow up of chronic posttransfusion non-A, non-B hepatitis : Clinical and histological outcome. Liver 8:184–188, 1988
   PubMedGoogle Scholar
• Marcellin P, Giostra E, Boyer N, Loriot M, Martinot-Peignoux M, Benhamou J. Is the response to recombinant alpha interferon related to the presence of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis? J Hepatol 11:77–79, 1990
   PubMedGoogle Scholar
• Hautekeete M, Marcellin P, Giostra E, Boyer N, Bettan L, Babany G, Degott C, Benhamou J. “Rebound” phenomenon after cessation of interferon-alfa therapy in chronic non-A non-B hepatitis (abstract). J Hepatol (suppl) 11:29, 1990
   Google Scholar
• Farrell G, Schoeman M, Craig P, MacDonald J, Batey R. Interferon alfa-2b for chronic active hepatitis C: Interim results of an Australian trial (abstract). J Hepatol (suppl) 11:157, 1990
   Google Scholar
• Giuliani-Piccari G, Sarti F, Spongano P, Macchia S, Dal Monte P. Recombinant Interferon alfa-2b in chronic NANB hepatitis therapy: Results of three treatment schedules (abstract). J Hepatol (suppl) 11:159, 1990
   Google Scholar
• Morra E, Alimena G, Lazzarino M, Liberati A, Montefusco E, Inverardi D, Mancini P, Bernasconi P, Grignani F, Dianzani F, Bernasconi C, Mandelli F. Treatment of Ph positive chronic myelogenous leukemia with interferon alpha-2b. New Trends Ther Leuk Lymph 2:75–82, 1987
   Google Scholar
• Golomb H, Fefer A, Golde D, Ozer H, Portlock C, Silber R, Rappeport J, Ratain M, Thompson J, Bonnem E, Spiegel R, Tensen L, Burke J, Vardiman J. Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia. Semin Oncology 14:13–17, 1987
   PubMed Web of Science ®Google Scholar
• Spiegel R. INTRON A (interferon alfa-2b): Clinical overview. Cancer Treatment Reviews (suppl B) 12:5–16, 1985
   Google Scholar
• Brook M, McDonald J, Karayiannis P, Caruso L, Forster G, Harris J, Thomas H. Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: Factors that influence response. Gut 30:1116–22, 1989
   PubMed Web of Science ®Google Scholar
• Jacyna M, Brooks M, Loke R, Main J, Murray-Lyon I, Thomas H. Randomized controlled trial of interferon alfa (lymfoblastoid interferon) in chronic non-A non-B hepatitis. Br Med J 298:80–2, 1989
   PubMed Web of Science ®Google Scholar
• Sherlock S. Hepatic cirrhosis. In: Diseases of the liver and biliary system. Blackwell Scientific Publications, Oxford, pp 410–24, 1989
   Google Scholar
• Schvarcz R, von Sydow M, Weiland O. Positive reactivity with anti-HCV ELISA in patients with autoimmune hepatitis - not confirmed with a neutralization test. Scand J Infect Dis 23:127–28, 1991
   PubMed Web of Science ®Google Scholar
• Rojkind M, Dunn M. Hepatic fibrosis. Gastroenterology 76:849–63, 1979
   PubMed Web of Science ®Google Scholar
• Cameron G, Karunaratne W. Carbon tetrachloride cirrhosis in relation to liver regeneration. J Pathol Bacteriol 42:1–21, 1936
   Google Scholar
• Morcos S, Khayyal M, Mansour M, Saleh S, Ishak E, Girgis N, Dunn M. Reversal of hepatic fibrosis after praziquantel therapy of murine schistosomiasis. Am J Trop Med Hyg 34:314–21,1985
   PubMed Web of Science ®Google Scholar
• Seyer J, Hutcheson E, Kang A. Collagen polymorphism in normal and cirrhotic human liver. J Clin Invest 59:241–48,1977
   PubMed Web of Science ®Google Scholar
• Welgus H, Jeffrey J, Eisen A. The collagen substrate specificity of human skin fibroblast collagenase. J Biol Chem 256:9511–15,1981
   PubMed Web of Science ®Google Scholar
• Soloway R, Baggenstoss A, Schoenfield L, Summerskill W. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 16:1082–86,1971
   PubMedGoogle Scholar
• Picciotto A, Ciravegna G, Lapertosa G, Celle G. Percutaneous or laparoscopic needle biopsy in the evaluation of chronic liver disease? Am J Gastroenterol 79:567–68,1984
   Google Scholar
• Czaja A. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 11:1044–49,1990
   PubMed Web of Science ®Google Scholar